✦ LIBER ✦

Infliximab (Remicade) treatment in Crohn's disease and antinuclear antibody (ANA) formation

✍ Scribed by Severine Vermeire; Maja Noman; Gert Van Assche; Nele Esters; Sofie Joossens; Filip Baert; Geert D'Haens; Freddy Cornillie; Thomas Schaible; Lieve Godefridis; Xavier Bossuyt; Paul Rutgeerts

Book ID: 119429205
Publisher: Elsevier Science
Year: 2001
Tongue: English
Weight: 199 KB
Volume: 120
Category: Article
ISSN: 0016-5085
DOI: 10.1016/s0016-5085(08)80340-x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Infliximab (REMICADE) therapy in the tre

Infliximab (REMICADE) therapy in the treatment of pediatric Crohn’s disease

✍ Robert Baldassano; Christian P Braegger; Johanna C Escher; Kimberly DeWoody; Dav 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 153 KB

HACA formation after infliximab (Remicad

HACA formation after infliximab (Remicade™) treatment in Crohn's disease is clearly associated with infusion reactions

✍ Noman, Maja; Baert, Flip; D'Haens, Geert; Van Assche, Gert; Swijsen, Caroline; A 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 164 KB

Infliximab (Remicade) maintenance treatm

Infliximab (Remicade) maintenance treatment strategy is superior to episodic treatment in patients with Crohn’s disease

✍ Paul Rutgeerts; Lloyd Mayer; Stephan Schreiber; Warren Bao; Mohan Bala; Greg Kee 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 39 KB

Infliximab (Remicade) treatment results

Infliximab (Remicade) treatment results in rapid quality of life improvement in patients with Crohn’s disease

✍ Brian Feagan; Chenglong Han; Mohan Bala; Allan Olson 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 30 KB

Outcome of pregnancy in women receiving

Outcome of pregnancy in women receiving REMICADE® (Infliximab) for the treatment of Crohn's disease or rheumatoid arthritis

✍ Jeffry A. Katz; Gary R. Lichtenstein; Gregory F. Keenan; Deirdre E. Healy; Steph 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 199 KB

Treatment of Crohn’s disease (CD): respo

Treatment of Crohn’s disease (CD): response to Remicade® (infliximab) in the ACCENT I trial through week 54

✍ Paul Rutgeerts; Jean-Frederick Colombel; Stephen Schreiber; Lloyd Mayer; Gary Li 📂 Article 📅 2001 🏛 Nature Publishing Group 🌐 English ⚖ 39 KB